Company Description
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide.
Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products.
The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease.
Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments.
It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain.
The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies.
The company was founded in 1949 and is headquartered in Dublin, Ireland.
| Country | Ireland |
| Founded | 1949 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 95,000 |
| CEO | Geoffrey Straub Martha |
Contact Details
Address: 20 On Hatch, Lower Hatch Street Dublin, L2 2 Ireland | |
| Phone | 01135314381700 |
| Website | medtronic.com |
Stock Details
| Ticker Symbol | MDT |
| Exchange | NYSE |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| CIK Code | 0001613103 |
| CUSIP Number | 585055106 |
| ISIN Number | IE00BTN1Y115 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Geoffrey Straub Martha | Chairman of the Board and Chief Executive Officer |
| Karen L. Parkhill | Executive Vice President and Chief Financial Officer |
| Sean M. Salmon | Executive Vice President and President of Cardiovascular Portfolio |
| Robert J. W. ten Hoedt | Executive Vice President and President of Global Regions |
| Mark Ploof | Senior Vice President of Global Operations and Business Services |
| Jennifer M. Kirk | Senior Vice President, Global Controller and Chief Accounting Officer |
| Dr. Kenneth E. Washington Ph.D. | Senior Vice President and Chief Technology and Innovation Officer |
| Dr. Laura Mauri M.D., M.Sc. | Senior Vice President and Chief Scientific, Medical and Regulatory Officer |
| Ryan Weispfenning | Vice President and Head of Investor Relations |
| Ivan K. Fong | Executive Vice President, General Counsel and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 27, 2024 | 10-Q | Quarterly Report |
| Feb 21, 2024 | 144 | Filing |
| Feb 20, 2024 | 8-K | Current Report |
| Feb 14, 2024 | 5 | Filing |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 19, 2023 | 144 | Filing |
| Dec 8, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |
| Dec 6, 2023 | 8-K | Current Report |
| Nov 30, 2023 | 10-Q | Quarterly Report |